Diabetic drug cuts kidney failure risk by a third
Canagliflozin also reduced the risk of major cardiovascular events by 20%
A glucose-lowering medication has been found to have striking benefits in reducing the risk of kidney failure in patients with type 2 diabetes, an Australian-led study has found.
And research leaders believe the renal benefits may be common to other drugs in the SGLT-2 inhibitor class.
